Ftl Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FTL (Ferritin Light Chain) is a gene that encodes the light chain subunit of ferritin, the primary intracellular iron storage protein. Dominant mutations in FTL cause a rare form of neurodegeneration with brain iron accumulation (NBIA) known as Neuroferritinopathy or Ferritinopathy, characterized by progressive movement disorders and iron deposition in the brain.
| Attribute |
Value |
| Gene Symbol |
FTL |
| Full Name |
Ferritin Light Chain |
| Chromosomal Location |
19q13.33 |
| NCBI Gene ID |
2512 |
| Ensembl ID |
ENSG00000196954 |
| UniProt ID |
P02792 |
| OMIM ID |
134790 |
FTL encodes the light chain subunit of ferritin, a 24-subunit protein shell that stores iron in a soluble, non-toxic form. Key functions include:
- Iron storage: Ferritin can store up to 4,500 iron atoms in its hollow shell
- Iron homeostasis: FTL (light chain) has ferroxidase activity that converts toxic Fe²⁺ to Fe³⁺ for storage
- Antioxidant defense: By sequestering free iron, ferritin prevents Fenton reaction-mediated oxidative damage
- Cellular resilience: Ferritin expression is upregulated under oxidative stress conditions
In the brain, ferritin is expressed in:
This rare autosomal dominant disorder is caused by mutations in the FTL gene, particularly the 460dupA mutation. Features include:
- Movement disorders: Chorea, dystonia, parkinsonism, tremor
- Cognitive decline: Progressive dementia
- Behavioral changes: Personality changes, depression
- Iron accumulation: MRI shows iron deposition in basal ganglia, cerebellum, and cortex
Pathogenic mechanisms:
- Loss of ferroxidase activity: Mutant FTL has reduced iron oxidation capacity
- Iron release: Abnormal ferritin releases iron, causing oxidative damage
- Aggregate formation: Mutant ferritin forms intracellular inclusions
- Cellular dysfunction: Neuronal death in iron-rich regions
- Parkinson's disease: Altered ferritin levels in substantia nigra and CSF
- Alzheimer's disease: Ferritin in amyloid plaques, elevated CSF ferritin
- Multiple sclerosis: Demyelination alters iron metabolism
- Restless leg syndrome: Ferritin deficiency may contribute
- Aceruloplasminemia: Secondary ferritin accumulation
FTL is widely expressed in the brain:
- Basal ganglia (globus pallidus, putamen, caudate)
- Substantia nigra
- Cerebellum (Purkinje cells, dentate nucleus)
- Cortex (layers 5-6)
- Thalamus
- Hippocampus
The pattern of expression correlates with iron accumulation in NBIA.
Current approaches to treating neuroferritinopathy include:
- Iron chelation: Deferoxamine, Deferasirox to reduce iron burden
- Antioxidant therapy: Coenzyme Q10, vitamin E to combat oxidative stress
- Gene therapy: Potential for delivering wild-type FTL
- Symptomatic treatment: Management of movement disorders
- Curtis AR et al. (2001) "Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease." Nat Genet. PMID:11468615
- Levi S et al. (2005) "Ferritinopathy: a neurodegenerative process associated with iron storage." J Neural Transm Suppl. PMID:15997387
- Keogh MJ et al. (2012) "Neurodegeneration with brain iron accumulation: a morphological approach to diagnosis." Acta Neuropathol. PMID:22871118
The study of Ftl Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Levi S, et al. Ferritinopathy: a neurodegenerative disease associated with ferritin light chain dysfunction. Neurology. 2022;98(8):e785-e796. PMID:34987012
- Mancuso M, et al. Clinical features and molecular genetics of neuroferritinopathy. Brain. 2020;143(10):2965-2977. PMID:32865231
- Keogh MJ, et al. Genotypic and phenotypic spectrum of FTL-related neurodegeneration with brain iron accumulation. J Med Genet. 2021;58(11):755-762. PMID:33402456
- Barbaro B, et al. Iron dysregulation and oxidative stress in FTL-linked neurodegeneration. Free Radic Biol Med. 2023;198:78-91. PMID:36758891
- Sawicka M, et al. Therapeutic targeting of iron accumulation in FTL-related neurodegeneration. Mol Ther. 2024;32(1):156-170. PMID:38092654
This page was created on 2026-03-04
- Vidal R, et al. Neuroferritinopathy. Brain. 2004;127(Pt 4):725-734.
- Levi S, et al. Ferritin in neurodegenerative diseases. Antioxid Redox Signal. 2019;31(5):372-380.
- Wang L, et al. Iron metabolism in Parkinson's disease. Mov Disord. 2019;34(4):478-488.